These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 10944799)

  • 1. Activation of skin dendritic cells by immunostimulatory DNA.
    Vogel JC; Udey MC
    Springer Semin Immunopathol; 2000; 22(1-2):45-54. PubMed ID: 10944799
    [No Abstract]   [Full Text] [Related]  

  • 2. Dendritic cells (DC) activated by CpG DNA ex vivo are potent inducers of host resistance to an intracellular pathogen that is independent of IL-12 derived from the immunizing DC.
    Ramírez-Pineda JR; Fröhlich A; Berberich C; Moll H
    J Immunol; 2004 May; 172(10):6281-9. PubMed ID: 15128817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bacterial lipoprotein-based vaccines induce tumor necrosis factor-dependent type 1 protective immunity against Leishmania major.
    Cote-Sierra J; Bredan A; Toldos CM; Stijlemans B; Brys L; Cornelis P; Segovia M; de Baetselier P; Revets H
    Infect Immun; 2002 Jan; 70(1):240-8. PubMed ID: 11748189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
    Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M
    Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis.
    Walker PS; Scharton-Kersten T; Rowton ED; Hengge U; Bouloc A; Udey MC; Vogel JC
    Hum Gene Ther; 1998 Sep; 9(13):1899-907. PubMed ID: 9741428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge.
    Stobie L; Gurunathan S; Prussin C; Sacks DL; Glaichenhaus N; Wu CY; Seder RA
    Proc Natl Acad Sci U S A; 2000 Jul; 97(15):8427-32. PubMed ID: 10890924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination with TAT-antigen fusion protein induces protective, CD8(+) T cell-mediated immunity against Leishmania major.
    Kronenberg K; Brosch S; Butsch F; Tada Y; Shibagaki N; Udey MC; von Stebut E
    J Invest Dermatol; 2010 Nov; 130(11):2602-10. PubMed ID: 20574442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge.
    Méndez S; Gurunathan S; Kamhawi S; Belkaid Y; Moga MA; Skeiky YA; Campos-Neto A; Reed S; Seder RA; Sacks D
    J Immunol; 2001 Apr; 166(8):5122-8. PubMed ID: 11290794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The immunodominant T helper 2 (Th2) response elicited in BALB/c mice by the Leishmania LiP2a and LiP2b acidic ribosomal proteins cannot be reverted by strong Th1 inducers.
    Iborra S; Abánades DR; Parody N; Carrión J; Risueño RM; Pineda MA; Bonay P; Alonso C; Soto M
    Clin Exp Immunol; 2007 Nov; 150(2):375-85. PubMed ID: 17900304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA.
    Jakob T; Walker PS; Krieg AM; Udey MC; Vogel JC
    J Immunol; 1998 Sep; 161(6):3042-9. PubMed ID: 9743369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic cells are responsible for the capacity of CpG oligodeoxynucleotides to act as an adjuvant for protective vaccine immunity against Leishmania major in mice.
    Shah JA; Darrah PA; Ambrozak DR; Turon TN; Mendez S; Kirman J; Wu CY; Glaichenhaus N; Seder RA
    J Exp Med; 2003 Jul; 198(2):281-91. PubMed ID: 12874261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination with Leishmania soluble antigen and immunostimulatory oligodeoxynucleotides induces specific immunity and protection against Leishmania donovani infection.
    Tewary P; Pandya J; Mehta J; Sukumaran B; Madhubala R
    FEMS Immunol Med Microbiol; 2004 Oct; 42(2):241-8. PubMed ID: 15364110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paradoxical effects of IL-12 in leishmaniasis in the presence and absence of vaccinating antigen.
    Noormohammadi AH; Hochrein H; Curtis JM; Baldwin TM; Handman E
    Vaccine; 2001 Jul; 19(28-29):4043-52. PubMed ID: 11427281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunomodulatory effects associated with a live vaccine against Leishmania major containing CpG oligodeoxynucleotides.
    Wu W; Weigand L; Belkaid Y; Mendez S
    Eur J Immunol; 2006 Dec; 36(12):3238-47. PubMed ID: 17109471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cell (DC)-based protection against an intracellular pathogen is dependent upon DC-derived IL-12 and can be induced by molecularly defined antigens.
    Berberich C; Ramírez-Pineda JR; Hambrecht C; Alber G; Skeiky YA; Moll H
    J Immunol; 2003 Mar; 170(6):3171-9. PubMed ID: 12626575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major.
    Afonso LC; Scharton TM; Vieira LQ; Wysocka M; Trinchieri G; Scott P
    Science; 1994 Jan; 263(5144):235-7. PubMed ID: 7904381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis.
    Coler RN; Skeiky YA; Bernards K; Greeson K; Carter D; Cornellison CD; Modabber F; Campos-Neto A; Reed SG
    Infect Immun; 2002 Aug; 70(8):4215-25. PubMed ID: 12117930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major.
    Gurunathan S; Sacks DL; Brown DR; Reiner SL; Charest H; Glaichenhaus N; Seder RA
    J Exp Med; 1997 Oct; 186(7):1137-47. PubMed ID: 9314562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TLR9-dependent activation of dendritic cells by DNA from Leishmania major favors Th1 cell development and the resolution of lesions.
    Abou Fakher FH; Rachinel N; Klimczak M; Louis J; Doyen N
    J Immunol; 2009 Feb; 182(3):1386-96. PubMed ID: 19155485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunization with Leishmania major exogenous antigens protects susceptible BALB/c mice against challenge infection with L. major.
    Tonui WK; Mejia JS; Hochberg L; Mbow ML; Ryan JR; Chan AS; Martin SK; Titus RG
    Infect Immun; 2004 Oct; 72(10):5654-61. PubMed ID: 15385463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.